As shown in Figure 9B–D, PMIBcr/Abl‐R6 potently inhibit BA/F3‐Bcr/Abl (T315I) tumors growth, while Bcr/Abl‐R6 only showed basal ability of tumor inhibition, imatinib as negative control showed no efficiency on BA/F3‐Bcr/Abl (T315I) tumors. Here, BCR is linked to neoplasm.